Raymond James Trust’s Corvus Pharmaceuticals CRVS Stock Holding History

Raymond James Trust’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,158	Closed	-$36K	–	985
2020 Q2	$36K	Hold	13,158	–	–	﹤0.01%	924
2020 Q1	$28K	Hold	13,158	–	–	﹤0.01%	816
2019 Q4	$72K	Hold	13,158	–	–	﹤0.01%	943
2019 Q3	$40K	Hold	13,158	–	–	﹤0.01%	936
2019 Q2	$49K	Hold	13,158	–	–	﹤0.01%	905
2019 Q1	$53K	Buy	+13,158	New	+$55.5K	﹤0.01%	871

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Trust's CRVS Position: Q3 2020 in Review

Raymond James Trust sold out of Corvus Pharmaceuticals (CRVS) in Q3 2020, closing a stake of 13,158 shares — an estimated $36K sold.

Raymond James Trust first reported a position in CRVS in Q1 2019 and held it in 6 quarters. The position peaked at $72K in Q4 2019. 38 funds tracked by Wall St. Rank hold CRVS as of Q3 2020.

Raymond James Trust reported no remaining Corvus Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Raymond James Trust sold 13,158 Corvus Pharmaceuticals shares in Q3 2020, an estimated $36K.
Raymond James Trust first reported a position in Corvus Pharmaceuticals in Q1 2019 and held it in 6 quarters.
Raymond James Trust's Corvus Pharmaceuticals position peaked at $72K in Q4 2019.
38 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2020.

Based on Raymond James Trust's 13F filing for Q3 2020, filed 14 Oct 2020.